Tharimmune (NASDAQ:THAR – Get Free Report) posted its earnings results on Tuesday. The company reported ($2.02) EPS for the quarter, Zacks reports.
Tharimmune Stock Performance
Tharimmune stock traded down $0.02 during midday trading on Thursday, reaching $1.43. 3,145 shares of the stock traded hands, compared to its average volume of 353,463. The company has a 50-day simple moving average of $1.75 and a two-hundred day simple moving average of $2.12. Tharimmune has a 12-month low of $1.28 and a 12-month high of $7.46.
Wall Street Analyst Weigh In
Several brokerages recently issued reports on THAR. RODMAN&RENSHAW upgraded shares of Tharimmune to a “strong-buy” rating in a report on Friday, December 6th. Rodman & Renshaw began coverage on shares of Tharimmune in a research report on Friday, December 6th. They set a “buy” rating and a $17.00 price objective for the company.
Tharimmune Company Profile
Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).
Featured Articles
- Five stocks we like better than Tharimmune
- Utilities Stocks Explained – How and Why to Invest in Utilities
- How China’s Recovery Could Boost These 3 Platinum Plays
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Fortinet: A Top Cybersecurity Stock With Growth Catalysts
- What is the Nikkei 225 index?
- 4 Reasons Amazon Stock Can’t Be Ignored Right Now
Receive News & Ratings for Tharimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tharimmune and related companies with MarketBeat.com's FREE daily email newsletter.
